aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
1.080
+0.065 (6.40%)
At close: Sep 16, 2025, 4:00 PM EDT
1.080
0.00 (0.00%)
Pre-market: Sep 17, 2025, 6:17 AM EDT

aTyr Pharma Statistics

Total Valuation

aTyr Pharma has a market cap or net worth of $105.83 million. The enterprise value is $38.16 million.

Market Cap105.83M
Enterprise Value 38.16M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, after market close.

Earnings Date Nov 6, 2025
Ex-Dividend Date n/a

Share Statistics

aTyr Pharma has 97.99 million shares outstanding. The number of shares has increased by 31.11% in one year.

Current Share Class 97.99M
Shares Outstanding 97.99M
Shares Change (YoY) +31.11%
Shares Change (QoQ) +4.20%
Owned by Insiders (%) 2.06%
Owned by Institutions (%) 68.83%
Float 95.97M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.34
P/TBV Ratio 1.41
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.63, with a Debt / Equity ratio of 0.17.

Current Ratio 5.63
Quick Ratio 5.21
Debt / Equity 0.17
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -85.39% and return on invested capital (ROIC) is -47.95%.

Return on Equity (ROE) -85.39%
Return on Assets (ROA) -42.20%
Return on Invested Capital (ROIC) -47.95%
Return on Capital Employed (ROCE) -81.45%
Revenue Per Employee n/a
Profits Per Employee -$1.03M
Employee Count65
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -43.16% in the last 52 weeks. The beta is 1.01, so aTyr Pharma's price volatility has been similar to the market average.

Beta (5Y) 1.01
52-Week Price Change -43.16%
50-Day Moving Average 5.19
200-Day Moving Average 4.12
Relative Strength Index (RSI) 22.44
Average Volume (20 Days) 14,429,438

Short Selling Information

The latest short interest is 29.41 million, so 30.01% of the outstanding shares have been sold short.

Short Interest 29.41M
Short Previous Month 28.25M
Short % of Shares Out 30.01%
Short % of Float 30.64%
Short Ratio (days to cover) 6.70

Income Statement

Revenue n/a
Gross Profit -54.23M
Operating Income -70.05M
Pretax Income -53.93M
Net Income -66.64M
EBITDA -69.36M
EBIT -70.05M
Earnings Per Share (EPS) -$0.80
Full Income Statement

Balance Sheet

The company has $80.35 million in cash and $12.68 million in debt, giving a net cash position of $67.67 million or $0.69 per share.

Cash & Cash Equivalents 80.35M
Total Debt 12.68M
Net Cash 67.67M
Net Cash Per Share $0.69
Equity (Book Value) 74.66M
Book Value Per Share 0.81
Working Capital 71.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$55.60 million and capital expenditures -$49,000, giving a free cash flow of -$55.65 million.

Operating Cash Flow -55.60M
Capital Expenditures -49,000
Free Cash Flow -55.65M
FCF Per Share -$0.57
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

aTyr Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -31.11%
Shareholder Yield -31.11%
Earnings Yield -62.97%
FCF Yield -52.59%

Analyst Forecast

The average price target for aTyr Pharma is $8.88, which is 722.22% higher than the current price. The consensus rating is "Buy".

Price Target $8.88
Price Target Difference 722.22%
Analyst Consensus Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 371.98%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.

Last Split Date Jul 1, 2019
Split Type Reverse
Split Ratio 1:14

Scores

aTyr Pharma has an Altman Z-Score of -3.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.48
Piotroski F-Score 1